Phoenixin-14

Synonyms: PNX-14
Phoenixin-14 (PNX-14) 是一种具有多种生物活性的内源性神经肽,也是 GPR173 的内源性配体,它通过抑制 HMGB1/TLR4/MyD88/NF-κB 信号轴降低 ROS 生成,从而发挥抗氧化和线粒体保护作用,并通过上调 SIRT3 表达、抑制 FOXO3 磷酸化来抑制凋亡 (apoptosis)、改善心肌收缩/舒张功能,同时通过激活 ATF4/SLC7A11/GPX4 轴抵抗铁死亡 (ferroptosis),并通过 GPR173 激活 ERK1/2 磷酸化,可用于神经保护、糖尿病、心肌病、生殖保护等研究。
产品编号: MS-R15795 纯度: 99.28% CAS No.: 1415039-79-0 分子式: C75H110N18O20 分子量: 1583.78
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Phoenixin-14 (PNX-14) 是一种具有多种生物活性的内源性神经肽,也是 GPR173 的内源性配体,它通过抑制 HMGB1/TLR4/MyD88/NF-κB 信号轴降低 ROS 生成,从而发挥抗氧化和线粒体保护作用,并通过上调 SIRT3 表达、抑制 FOXO3 磷酸化来抑制凋亡 (apoptosis)、改善心肌收缩/舒张功能,同时通过激活 ATF4/SLC7A11/GPX4 轴抵抗铁死亡 (ferroptosis),并通过 GPR173 激活 ERK1/2 磷酸化,可用于神经保护、糖尿病、心肌病、生殖保护等研究。

生物实验数据

生物活性 Phoenixin-14 (PNX-14) is an endogenous neuropeptide with multiple biological activities and an endogenous ligand of GPR173 that exerts antioxidant and mitochondrial protective effects by inhibiting the HMGB1/TLR4/MyD88/NF-κB signaling axis to reduce ROS generation, inhibits apoptosis and improves myocardial systolic/diastolic function by upregulating SIRT3 expression and inhibiting FOXO3 phosphorylation, confers resistance to ferroptosis by activating the ATF4/SLC7A11/GPX4 axis, and activates ERK1/2 phosphorylation via GPR173, making it applicable to research in neuroprotection, diabetes, cardiomyopathy, reproductive protection, and other fields.
IC50 & Target

ERK1

 

ERK2

 

GPX4

 

SIRT3

 

FOXO3

 

体外研究
(In Vitro)

Phoenixin-14 (1-1000 nM; 24 h) 可通过上调类固醇生成酶的表达,直接刺激发情周期第 10-12 天的猪黄体细胞分泌孕酮和雌二醇;而与黄体生成素 (LH) (MS-K46438) 联合处理则会减弱孕酮的分泌及类固醇生成酶的表达。
Phoenixin-14 (1-1000 nM; 24 h) 可通过升高 PGE2 水平、降低 PGF2α 水平,同时下调前列腺素受体表达,来调控发情周期第 10-12 天猪黄体细胞的前列腺素分泌。
Phoenixin-14 (1-1000 nM; 24 h) 可上调发情周期第 10-12 天猪黄体细胞中 GPR173 蛋白的表达,并激活多条激酶信号通路,包括增强 ERK1/2 和 AKT 的磷酸化、降低 PKA 的磷酸化,以及对 AMPKα 和 PKC 的磷酸化产生时间依赖性的混合效应。
Phoenixin-14 (10 nM; 24 h) 对发情周期第 10-12 天猪黄体细胞中类固醇和前列腺素分泌的促黄体作用是通过 GPR173 及 ERK1/2 信号通路介导的,而不依赖于 PKA 通路。
Phoenixin-14 (50-100 nM; 24 h) 可通过恢复 ATF4/SLC7A11/GPX4 轴,呈剂量依赖性缓解顺铂诱导的 KGN 细胞损伤、氧化应激和铁死亡。
Phoenixin-14 (5-10 nM; 30 h) 可呈剂量依赖性抑制 OGD/R 诱导的 BV2 小胶质细胞中 TNF-α、IL-1β 和 IL-6 的 mRNA 及蛋白水平升高。
Phoenixin-14 (5-10 nM; 30 h) 可呈剂量依赖性降低 BV2 小胶质细胞中 OGD/R 诱导的 ROS 生成,并恢复被消耗的 GSH 水平。
Phoenixin-14 (5-10 nM; 30 h) 可剂量依赖性逆转 BV2 小胶质细胞中 OGD/R 诱导的线粒体膜电位降低,其中 10 nM 剂量几乎可完全消除该降低效应。
Phoenixin-14 (5-10 nM; 30 h) 可呈剂量依赖性地减轻 OGD/R 诱导的 BV2 小胶质细胞活力下降,其中 10 nM 剂量几乎可维持细胞的基线活力。
Phoenixin-14 (5-10 nM; 30 h) 可呈剂量依赖性抑制 BV2 小胶质细胞中 OGD/R 诱导的 HMGB1 蛋白水平升高。
Phoenixin-14 (5-10 nM; 30 h) 可呈剂量依赖性抑制 OGD/R 诱导的 BV2 小胶质细胞中 TLR4 和 MyD88 的 mRNA 及蛋白水平升高。
Phoenixin-14 (5-10 nM; 30 h) 可呈剂量依赖性抑制 BV2 小胶质细胞中 OGD/R 诱导的 NF-κB p65 核转位及 NF-κB 荧光素酶活性激活。
Phoenixin-14 (10 nM; 30 h) 对 BV2 小胶质细胞的 OGD/R 损伤具有保护性抗炎作用,该作用依赖于 GPR173 信号通路。
Phoenixin-14 (100 nM; 24 h) 可逆转由 iSMC 和 SMC 条件培养基诱导的人脐静脉内皮细胞活力、血管生成及迁移能力的下降,并可逆转其诱导的细胞凋亡。

Cell Viability Assay

Cell Line: human granulosa cell line KGN cells
Concentration: 50 nM, 100 nM
Incubation Time: 24 h
Result: Restored cisplatin-reduced KGN cell viability from 47.8% to 61.7% (50 nM) and 79.2% (100 nM).
Reduced cisplatin-increased LDH release from 35.9% to 29.3% (50 nM) and 23.6% (100 nM).
Dose-dependently suppressed cisplatin-increased mitochondrial ROS, total cellular ROS, and MDA levels (from 13.4 μmol/mg protein), and restored SOD activity from 12.6 U/mg protein to 15.5 U/mg protein (50 nM) and 19.8 U/mg protein (100 nM).
Dose-dependently reduced cisplatin-increased Fe2+ levels and restored cisplatin-downregulated SLC7A11 and GPX4 expression.
Dose-dependently restored cisplatin-downregulated ATF4 expression.
Exhibited no significant effect on cisplatin-induced caspase-3 activity.
Improved cisplatin-reduced cell viability, reduced Fe2+ levels, and reduced MDA levels to a similar extent as 1 μM ferrostatin-1, with no additive effect when combined.
Silencing ATF4 abolished PNX-14's protective effects, including increased LDH release from 22.5% to 30.7%, increased MDA levels from 8.6 to 12.5 μmol/mg protein, decreased SOD activity from 19.2 to 14.3 U/mg protein, and reversed restoration of SLC7A11/GPX4 expression.

Cell Viability Assay

Cell Line: murine microglial BV2 cells
Concentration: 5 and 10 nM
Incubation Time: 6 h pretreatment followed by reoxygenation for 24 h
Result: Limited OGD/R-induced cell viability reduction from 58% to 27% and 4%, respectively, in a dose-responsive manner.

ELISA Assay

Cell Line: murine microglial BV2 cells
Concentration: 5 and 10 nM
Incubation Time: 6 h pretreatment followed by reoxygenation for 24 h
Result: Reduced OGD/R-induced HMGB1 expression increase from roughly 6.5-fold to 2.4-fold in a dose-responsive manner.
体内研究
(In Vivo)

Phoenixin-14 (50 μg/kg;腹腔注射;每日 1 次;连续 3 天) 可提升雌性 Sprague-Dawley 大鼠的体质量与卵巢重量,恢复卵巢卵泡发育,并通过 ATF4/SLC7A11/GPX4 轴抑制铁死亡,从而缓解顺铂诱导的卵巢早衰。
Phoenixin-14 (100 mg/kg;腹腔注射;每日一次;持续 2 个月) 可通过改善心脏功能、减轻心肌损伤、缓解心肌肥大、减轻氧化应激与炎症反应及恢复 SIRT3/FOXO3 信号通路,对链脲佐菌素 (STZ) (MS-Q80520) 诱导的 C57BL/6 小鼠糖尿病心肌病起到保护作用,且对正常小鼠无明显作用。
Phoenixin-14 (15 nmol;侧脑室注射;单次给药) 可将大鼠大脑中动脉闭塞 (MCAO) 缺血性卒中模型中缺血/再灌注诱导的脑梗死体积降低至不足 20%,并抑制小胶质细胞活化。

Animal Model: Sprague-Dawley (SD) (female, 6-8 weeks old, cisplatin-induced POF)
Dosage: 50 μg/kg
Administration: i.p.; daily; 3 days
Result: Increased body weight from 165.7 g to 194.5 g.
Increased ovary weight from 38.5 mg to 47.3 mg.
Reduced the ratio of growing follicles to primordial follicles from 2.05 to 1.38.
Reduced ovarian tissue MDA levels from 11.26 nmol/mL to 8.32 nmol/mL.
Increased SOD activity from 12.19 U/mL to 17.79 U/mL.
Mitigated elevated Fe2+ levels.
Restored suppressed mRNA and protein expression of ATF4, SLC7A11, and GPX4.
Exerted minimal effects on these parameters in healthy control rats.
Animal Model: C57BL/6
Dosage: 100 mg/kg
Administration: i.p.; daily; 2 months
Result: Reduced elevated heart rate from 536.8 beats/min to levels comparable to control mice.
Suppressed elevated mean arterial pressure from 128.4 mmHg to 115.3 mmHg.
Slightly reduced fasting blood glucose from 17.65 mmol/L to 16.24 mmol/L.
Significantly decreased serum myocardial injury markers CK-MB, AST, and LDH from STZ-induced elevated levels.
Restored ejection fraction from 71.4% to 80.6% and fractional shortening from 46.6% to 58.7%.
Reduced WGA staining intensity fold change from 5.5 to ~2.5 and suppressed STZ-induced elevated gene expression of ANP, BNP, and β-MHC.
Reduced cardiac hydrogen peroxide levels from 33.8 μmol/g protein to 25.6 μmol/g protein.
Increased cardiac GSH levels from 98.5 μg/g protein to 138.8 μg/g protein.
Increased cardiac GPx levels from 1268.7 mu/g protein to 2105.4 mu/g protein.
Decreased serum TNF-β from 34.4 pg/mL to 18.4 pg/mL and serum IL-6 from 214.3 pg/mL to 154.2 pg/mL.
Decreased cardiac TNF-β from 1.21 ng/g protein to 0.72 ng/g protein and cardiac IL-6 from 1.45 ng/g protein to 0.91 ng/g protein.
Reversed STZ-induced downregulation of cardiac SIRT3 protein levels and upregulation of cardiac p-FOXO3 protein levels.
Caused no significant changes to heart rate, mean arterial pressure, body weight, food/water intake, fasting blood glucose, myocardial injury markers, ejection fraction, fractional shortening, cardiac hypertrophy markers, oxidative stress markers, inflammatory markers, or SIRT3/FOXO3 protein levels in normal mice compared to untreated controls.
Animal Model: Sprague-Dawley (male, adult, 260-345 g, middle cerebral artery occlusion model)
Dosage: 15 nmol
Administration: i.c.v.; single dose; 1 h prior to MCAO
Result: Reduced MCAO-induced brain infarct volume from ~36% to just under 20%.
Reduced MCAO-induced CD11b expression increase from 2.5-fold relative to sham controls to 1.4-fold.
Significantly reduced Iba1 expression (a microglial activation marker) compared to MCAO-only rats.
性状 固体
颜色 White to off-white

化学信息

分子量 1583.78
分子式 C75H110N18O20
CAS No. 1415039-79-0
别名 PNX-14

储存&溶解度

储存方式

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (63.14 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.6314 mL3.1570 mL6.3140 mL15.7850 mL
5 mM0.1263 mL0.6314 mL1.2628 mL3.1570 mL
10 mM0.0631 mL0.3157 mL0.6314 mL1.5785 mL
15 mM0.0421 mL0.2105 mL0.4209 mL1.0523 mL
20 mM0.0316 mL0.1579 mL0.3157 mL0.7893 mL
25 mM0.0253 mL0.1263 mL0.2526 mL0.6314 mL
30 mM0.0210 mL0.1052 mL0.2105 mL0.5262 mL
40 mM0.0158 mL0.0789 mL0.1579 mL0.3946 mL
50 mM0.0126 mL0.0631 mL0.1263 mL0.3157 mL
60 mM0.0105 mL0.0526 mL0.1052 mL0.2631 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Phoenixin-14 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础